Pfizer releases promising data on its COVID-19 pill; Republican state officials push back on President Joe Biden's vaccine mandate; some spray deodorants may contain high levels of cancer-causing chemicals.
Data released by Pfizer show that the company’s experimental COVID-19 antiviral pill reduced the risk of death and hospitalization by 89% among patients with newly diagnosed disease, STAT News reports. The pill could signify a turning point in the pandemic, as currently available treatments need to be administered intravenously or as shots. Although data have not been peer reviewed or submitted to regulators, some experts called the news very promising. The announcement comes a day after Merck’s COVID-19 pill was approved in the United Kingdom.
In the wake of President Joe Biden’s release of a more detailed plan for large private employers to vaccinate their workers, several Republican state officials have expressed their objection to the measure and are working to rebuke it, according to the Associated Press. The officials see the plan, which mandates COVID-19 vaccines or weekly testing among employees, as government overreach, and at least 2 conservative groups have already filed lawsuits against implementation. Some states also already passed laws or executive orders to protect employers unwilling to comply.
An independent testing lab in Connecticut filed a petition with the FDA claiming antiperspirant and deodorant body sprays should be recalled because they contain elevated levels of the carcinogen benzene, Bloomberg reports. The cancer-causing chemical has previously been found in aerosol sunscreens and antifungals, while earlier this year Johnson & Johnson recalled certain sunscreen sprays under its Neutrogena and Aveeno brands. Valisure, the testing lab, tested 108 batches of antiperspirant and deodorant sprays and found benzene in 59 batches at levels up to triple the amount found in sunscreens.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More